Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1985 1
1990 1
1993 1
1994 2
1995 2
1997 3
1998 2
1999 2
2001 3
2002 1
2004 3
2005 4
2006 4
2007 1
2008 4
2009 7
2010 10
2011 2
2012 8
2013 5
2014 10
2015 11
2016 7
2017 10
2018 13
2019 16
2020 27
2021 27
2022 21
2023 14
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Results by year

Filters applied: . Clear all
Page 1
Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease.
Langlois F, Varlamov EV, Fleseriu M. Langlois F, et al. J Clin Endocrinol Metab. 2022 Jan 1;107(1):10-28. doi: 10.1210/clinem/dgab672. J Clin Endocrinol Metab. 2022. PMID: 34528683 Free PMC article. Review.
Hypophysitis is defined as inflammation of the pituitary gland that is primary or secondary to a local or systemic process. ...Novel pathologies such as immunoglobulin G4-related hypophysitis, immunotherapy-induced hypophysitis, and paraneoplastic pituitary-d …
Hypophysitis is defined as inflammation of the pituitary gland that is primary or secondary to a local or systemic process. ...Novel …
Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS, Kähler KC, Hauschild A. Weber JS, et al. J Clin Oncol. 2012 Jul 20;30(21):2691-7. doi: 10.1200/JCO.2012.41.6750. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614989 Review.
These include rashes, which may rarely progress to life-threatening toxic epidermal necrolysis, and colitis, characterized by a mild to moderate, but occasionally also severe and persistent diarrhea. Hypophysitis, hepatitis, pancreatitis, iridocyclitis, lymphadenopathy, ne …
These include rashes, which may rarely progress to life-threatening toxic epidermal necrolysis, and colitis, characterized by a mild to mode …
Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T, Liaw B, Asada M, Niimura T, Zamami Y, Green-LaRoche D, Pai L, Levy M, Jeyapalan S. Mikami T, et al. J Neurooncol. 2021 Mar;152(1):135-144. doi: 10.1007/s11060-020-03687-2. Epub 2021 Jan 9. J Neurooncol. 2021. PMID: 33423151
PURPOSE: To investigate the characteristics and risk factors for neurologic adverse events (AEs) induced by immune checkpoint inhibitors (ICIs). METHODS: An observational, retrospective, and pharmacovigilance study based on the FAERS database collected between January 2014 …
PURPOSE: To investigate the characteristics and risk factors for neurologic adverse events (AEs) induced by immune checkpoint inhibitors (IC …
Cancer immunotherapy-associated hypophysitis.
Solinas C, Porcu M, De Silva P, Musi M, Aspeslagh S, Scartozzi M, Willard-Gallo K, Mariotti S, Saba L. Solinas C, et al. Semin Oncol. 2018 Jun;45(3):181-186. doi: 10.1053/j.seminoncol.2018.09.002. Epub 2018 Oct 21. Semin Oncol. 2018. PMID: 30352754 Review.
Hypophysitis with immune checkpoint blockade requires early recognition, diagnosis, and treatment. ...A multidisciplinary team approach is merited to insure the correct diagnosis and management of immune-related hypophysitis....
Hypophysitis with immune checkpoint blockade requires early recognition, diagnosis, and treatment. ...A multidisciplinary team approa …
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.
Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, Moschos SJ, Atkins MB, Lewis K, Postow MA, Thomas RP, Glaspy J, Jang S, Khushalani NI, Pavlick AC, Ernstoff MS, Reardon DA, Kudchadkar R, Tarhini A, Chung C, Ritchings C, Durani P, Askelson M, Puzanov I, Margolin KA. Tawbi HA, et al. Lancet Oncol. 2021 Dec;22(12):1692-1704. doi: 10.1016/S1470-2045(21)00545-3. Epub 2021 Nov 10. Lancet Oncol. 2021. PMID: 34774225 Free PMC article. Clinical Trial.
FINDINGS: Between Feb 19, 2015, and Nov 1, 2017, 119 (72%) of 165 screened patients were enrolled and treated: 101 patients were asymptomatic (cohort A; median follow-up 34.3 months [IQR 14.7-36.4]) and 18 were symptomatic (cohort B; median follow-up 7.5 months [1.2-35.2]). Inves …
FINDINGS: Between Feb 19, 2015, and Nov 1, 2017, 119 (72%) of 165 screened patients were enrolled and treated: 101 patients were asymptomati …
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Qian DC, Kleber T, Brammer B, Xu KM, Switchenko JM, Janopaul-Naylor JR, Zhong J, Yushak ML, Harvey RD, Paulos CM, Lawson DH, Khan MK, Kudchadkar RR, Buchwald ZS. Qian DC, et al. Lancet Oncol. 2021 Dec;22(12):1777-1786. doi: 10.1016/S1470-2045(21)00546-5. Epub 2021 Nov 12. Lancet Oncol. 2021. PMID: 34780711 Clinical Trial.
We calculated the association between overall survival and proportion of infusions of immune checkpoint inhibitors received after 1630 h (a composite time cutoff derived from seminal studies of the immune-circadian rhythm to represent onset of evening) using Cox regression and pr …
We calculated the association between overall survival and proportion of infusions of immune checkpoint inhibitors received after 1630 h (a …
Imaging findings in hypophysitis: a review.
Caranci F, Leone G, Ponsiglione A, Muto M, Tortora F, Muto M, Cirillo S, Brunese L, Cerase A. Caranci F, et al. Radiol Med. 2020 Mar;125(3):319-328. doi: 10.1007/s11547-019-01120-x. Epub 2019 Dec 20. Radiol Med. 2020. PMID: 31863360 Review.
Hypophysitis (HP) is a rare acute or chronic inflammatory condition of the pituitary gland. The greatest challenge in the management of HP is establishing a diagnosis through clinical criteria and non-invasive methods and predicting the patients' clinical outcome. T …
Hypophysitis (HP) is a rare acute or chronic inflammatory condition of the pituitary gland. The greatest challenge in the management …
Critical review of IgG4-related hypophysitis.
Shikuma J, Kan K, Ito R, Hara K, Sakai H, Miwa T, Kanazawa A, Odawara M. Shikuma J, et al. Pituitary. 2017 Apr;20(2):282-291. doi: 10.1007/s11102-016-0773-7. Pituitary. 2017. PMID: 27812776 Review.
PURPOSE: IgG4-related hypophysitis is a rare disease, with only 34 cases published in English (2015). Available short reviews may not present complete details of IgG4-related hypophysitis. We aimed to survey case reports of IgG4-related hypophysitis, includin …
PURPOSE: IgG4-related hypophysitis is a rare disease, with only 34 cases published in English (2015). Available short reviews may not …
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.
Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Yoo SY, Mathias M, Han H, Seebach F, Lowy I, Fury MG, Rischin D. Gross ND, et al. Lancet Oncol. 2023 Nov;24(11):1196-1205. doi: 10.1016/S1470-2045(23)00459-X. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875144 Clinical Trial.
After surgery, per investigator discretion, patients received either adjuvant cemiplimab for up to 48 weeks, radiotherapy, or observation alone. Secondary endpoints included in this follow-up analysis are event-free survival, disease-free survival, and overall survival, al …
After surgery, per investigator discretion, patients received either adjuvant cemiplimab for up to 48 weeks, radiotherapy, or observation …
Neurology of the pituitary.
Samarasinghe S, Emanuele MA, Mazhari A. Samarasinghe S, et al. Handb Clin Neurol. 2014;120:685-701. doi: 10.1016/B978-0-7020-4087-0.00047-4. Handb Clin Neurol. 2014. PMID: 24365347 Review.
While the most common cause of a pituitary mass is an adenoma, the differential diagnosis is broad and includes pituitary hyperplasia, lymphocytic hypophysitis, craniopharyngioma among others. Patients with pituitary adenomas can be asymptomatic or present with symptoms du …
While the most common cause of a pituitary mass is an adenoma, the differential diagnosis is broad and includes pituitary hyperplasia, lymph …
209 results